- Report
- January 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- February 2024
- 120 Pages
Global
From €4558EUR$4,750USD£3,925GBP
- Report
- March 2024
- 580 Pages
Global
From €6712EUR$6,995USD£5,781GBP
- Report
- December 2023
- 198 Pages
Global
From €4749EUR$4,950USD£4,091GBP
- Report
- May 2024
- 183 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- December 2023
- 200 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- January 2024
- 92 Pages
Europe
From €2830EUR$2,950USD£2,438GBP
- Report
- November 2022
- 295 Pages
Global
From €4749EUR$4,950USD£4,091GBP
- Report
- March 2019
- 255 Pages
Global
From €1187EUR$1,238USD£1,023GBP
€2375EUR$2,475USD£2,045GBP
- Report
- November 2019
- 162 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- March 2022
- 117 Pages
Global
From €4270EUR$4,450USD£3,678GBP
- Report
- September 2023
- 140 Pages
Global
From €2877EUR$2,999USD£2,478GBP
The Cancer Profiling market within the Diagnostics industry is focused on the development of tests that can detect the presence of cancer in a patient. These tests are used to identify the type of cancer, its stage, and the best treatment options. Cancer profiling tests are used to detect genetic mutations, which can help doctors determine the best course of treatment for a patient. These tests are also used to monitor the progress of a patient's cancer treatment.
The Cancer Profiling market is highly competitive, with many companies offering a variety of tests. Some of the major players in the market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Roche. Show Less Read more
